©IDOSR PUBLICATIONS International Digital Organization for Scientific Research

IDOSR JOURNAL OF APPLIED SCIENCES 11(2):28-34, 2026 ISSN: 2550-7931

https://doi.org/10.59298/IDOSRJAS/2026/1122834 IDOSRJAS11200

Cross-Disease Hepatic Complications: How Diabetes, Autoantibodies, and Drug Toxicity Converge

Twesigye Davis

Department of Pharmacognosy Kampala International University Uganda
Email: twesigyedavis@studwc.kiu.ac.ug

ABSTRACT

Hepatic complications frequently arise at the intersection of metabolic disease, immune dysregulation, and xenobiotic injury. Diabetes mellitus, autoimmune processes marked by autoantibodies, and drug-induced liver toxicity represent distinct clinical entities, yet they converge mechanistically and clinically in ways that significantly impact liver health. Insulin resistance, chronic hyperglycemia, and altered lipid metabolism in diabetes predispose the liver to steatosis, inflammation, and fibrosis, establishing a vulnerable baseline that amplifies damage from immune-mediated and toxic insults. Autoantibodies directed against hepatic antigens contribute to autoimmune hepatitis and overlap syndromes, driving inflammatory pathways that can coexist with metabolic dysfunction. Drug toxicity-whether from therapeutic agents, herbal supplements, or environmental chemicals-exerts direct hepatocellular injury through metabolic activation and oxidative stress, but can also trigger or amplify immune responses. This review examines shared mechanisms linking these conditions, including oxidative stress, endoplasmic reticulum dysfunction, immune cell activation, alterations in the gut-liver axis, and genetic/epigenetic susceptibility. Recognizing common pathways not only improves diagnosis and management but also highlights opportunities for integrated therapeutic strategies targeting inflammation, metabolism, and detoxification. Understanding these convergent mechanisms is essential for clinicians and researchers seeking to reduce the burden of chronic liver disease in complex systemic disorders.

Keywords: liver disease; diabetes mellitus; autoantibodies; drug-induced liver injury; immune-metabolic interactions

INTRODUCTION

The liver plays a central role in maintaining systemic homeostasis through its integrated functions in metabolism, detoxification, and immune surveillance[1-4]. As the primary site for glucose and lipid metabolism, xenobiotic biotransformation, and clearance of circulating antigens, the liver is continuously exposed to metabolic by-products, immune signals, and potentially harmful compounds[5-6]. This unique positioning renders it particularly vulnerable to injury arising from metabolic disturbances, immune-mediated mechanisms, and drug-related toxicity[7-9]. Diabetes mellitus, autoimmune conditions characterized by pathogenic autoantibodies, and drug-induced liver injury are each well-established causes of hepatic dysfunction and chronic liver disease. In clinical practice, however, these conditions rarely occur in isolation[10-13]. Increasingly, patients present with overlapping metabolic and immune abnormalities while being exposed to multiple therapeutic or environmental agents. Diabetes creates a metabolically stressed hepatic environment marked by insulin resistance, oxidative stress, and lipid accumulation, which can lower the threshold for immune-mediated or toxic injury[14–17]. Concurrently, autoimmune processes driven by autoantibodies and autoreactive lymphocytes can amplify

inflammation and impair hepatocellular resilience[18-21]. Drug toxicity further compounds this vulnerability by generating reactive metabolites and oxidative damage that can trigger or exacerbate immune responses.

This convergence reflects shared molecular and cellular pathways, including mitochondrial dysfunction, redox imbalance, endoplasmic reticulum stress, and dysregulated immune signaling[22-25]. Understanding how these mechanisms intersect is essential for explaining the severity and heterogeneity of hepatic complications observed in complex systemic diseases[26-28]. This review explores the mechanistic intersections linking diabetes, autoantibodies, and drug toxicity to liver injury, with particular emphasis on oxidative stress, immune–metabolic cross-talk, and their clinical implications[29-31].

2. Diabetes and Liver Injury: Metabolic Stress as a Foundation

Diabetes mellitus, particularly type 2 diabetes mellitus (T2DM), establishes a metabolic milieu that strongly predisposes the liver to injury[32-35]. As insulin resistance develops, hepatic glucose and lipid handling become dysregulated, leading to increased de novo lipogenesis and impaired lipid export. These alterations promote the accumulation of triglycerides within hepatocytes, giving rise to non-alcoholic fatty liver disease (NAFLD), now recognized as one of the most common chronic liver disorders worldwide[36-39]. NAFLD represents a disease spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), a more aggressive form characterized by hepatocyte ballooning, inflammatory infiltration, and progressive fibrosis[40-43]. Because the liver serves as a central metabolic hub, it is particularly vulnerable to the downstream effects of systemic hyperglycemia and lipid overload.

2.2 Underlying Mechanisms: Oxidative and ER Stress

At the cellular level, hyperglycemia and excess free fatty acids drive oxidative and endoplasmic reticulum stress[44-46]. Increased glucose flux through mitochondria enhances reactive oxygen species production, while chronic nutrient excess overwhelms endogenous antioxidant defenses[47-49]. Simultaneously, excessive fatty acid delivery saturates β-oxidation pathways and disrupts protein folding within the endoplasmic reticulum, triggering activation of the unfolded protein response[50-54]. Although initially protective, prolonged unfolded protein response signaling promotes hepatocyte apoptosis and the release of inflammatory mediators, which attract immune cells to the liver and amplify tissue injury.

2.3 Insulin Resistance and Inflammation

Insulin resistance further links metabolic stress to inflammation[16,55-56]. In the insulin-resistant liver, gluconeogenesis and dyslipidemia are exaggerated, reinforcing metabolic imbalance. Dysfunctional adipose tissue in diabetes becomes an active source of pro-inflammatory cytokines such as tumor necrosis factor-α and interleukin-6[57-58]. These circulating factors activate Kupffer cells, the liver-resident macrophages, leading to local production of cytokines and reactive oxygen species[59-60]. This creates a self-sustaining cycle in which metabolic stress and immune activation reinforce one another, laying a foundation for progressive liver damage[61-62].

3. Autoantibodies and Immune-Mediated Liver Damage

3.1 Autoimmune Hepatitis and Serologic Markers

Autoimmune hepatitis (AIH) is a prototypical immune-mediated liver disease characterized by chronic hepatic inflammation, interface hepatitis, and the presence of circulating autoantibodies[20]. Commonly detected serologic markers include antinuclear antibodies (ANA), smooth muscle antibodies (SMA), and liver–kidney microsomal antibodies (anti-LKM), which are used clinically for diagnosis and disease classification[21]. Although these autoantibodies are not always directly cytotoxic, they signify a profound loss of immune tolerance to hepatic antigens. Autoantibody–antigen interactions can promote immune complex deposition and complement activation within the liver, enhancing local inflammation[22]. In parallel, their presence reflects ongoing B-cell activation and provides a biomarker of immune dysregulation that correlates with disease severity and treatment response.

3.2 Immune Mechanisms of Hepatic Injury

The immunopathogenesis of AIH involves coordinated actions of innate and adaptive immune cells[23]. Antigen-presenting cells, including dendritic cells and Kupffer cells, present self-antigens under pro-inflammatory conditions, favoring the activation of autoreactive $CD4^+$ and $CD8^+$ T cells[24]. Cytotoxic T lymphocytes induce hepatocyte apoptosis through perforin–granzyme pathways and Fas–Fas ligand signaling. Concurrently, activated B cells differentiate into plasma cells that sustain autoantibody production[25]. Pro-inflammatory cytokines such as interferon-γ, tumor necrosis factor-α, and interleukin-17 amplify immune cell recruitment and activation, creating a self-reinforcing inflammatory milieu that drives chronic liver injury and fibrosis.

3.3 Autoimmunity in the Context of Diabetes

Autoimmune processes frequently intersect with metabolic disease[26]. Type 1 diabetes mellitus, and subsets of type 2 diabetes with autoimmune features, share genetic susceptibility loci, particularly certain HLA alleles, with autoimmune liver diseases[27]. In autoimmune polyglandular syndromes, pancreatic autoimmunity may coexist with hepatic autoantibody production, predisposing patients to combined endocrine and hepatic dysfunction[28]. When autoimmune activation coincides with diabetic metabolic stress, hepatocytes become more vulnerable to immune-mediated damage, accelerating inflammation and disease progression.

4. Drug-Induced Liver Injury: Toxicity Meets Immune Activation

4.1 Spectrum of Drug-Induced Liver Injury

Drug-induced liver injury (DILI) represents a significant cause of acute and chronic hepatic dysfunction worldwide, encompassing hepatotoxicity from prescription medications, over-the-counter drugs, herbal and dietary supplements, and environmental chemicals[29]. Clinically, DILI exhibits a wide spectrum of manifestations, ranging from mild, asymptomatic elevations in liver enzymes to severe presentations including fulminant hepatic failure[30]. Two broad categories are recognized: intrinsic and idiosyncratic DILI. Intrinsic DILI is predictable and dose-dependent, exemplified by acetaminophen toxicity, where excessive metabolic activation produces reactive intermediates that directly injure hepatocytes[31]. Idiosyncratic DILI, by contrast, is unpredictable and often occurs at therapeutic doses, with immune-mediated mechanisms playing a prominent role. It may manifest as hepatocellular, cholestatic, or mixed injury patterns and frequently mimics autoimmune hepatitis both clinically and histologically.

4.2 Mechanisms: Reactive Metabolites and Oxidative Stress

The pathophysiology of DILI involves the generation of reactive metabolites during hepatic biotransformation[32]. Many xenobiotics are metabolized by cytochrome P450 enzymes into electrophilic intermediates that covalently bind to cellular macromolecules, including proteins, lipids, and DNA. These adducts disrupt mitochondrial function, impair ATP synthesis, and enhance reactive oxygen species (ROS) production, promoting oxidative stress and lipid peroxidation[33]. Concomitant endoplasmic reticulum stress is often triggered, activating the unfolded protein response and pro-apoptotic pathways. Susceptibility to DILI varies depending on genetic polymorphisms in metabolic enzymes, antioxidant capacity, and pre-existing liver stressors, such as metabolic dysfunction or chronic inflammation[34]. In severe cases, these processes culminate in hepatocyte necrosis or apoptosis, triggering secondary inflammatory responses that amplify tissue injury.

4.3 Immune Sensitization and Autoimmune Features

Reactive metabolites can modify native hepatic proteins to create neoantigens, which are recognized by the immune system as foreign[35]. This neoantigen formation can activate adaptive immune responses, involving drug-specific T cells and the production of autoantibodies, thereby bridging toxic and immune-mediated pathways[36]. Some cases of DILI present with serologic and histologic features similar to autoimmune hepatitis, including antinuclear antibody positivity, lymphoplasmacytic infiltration, and interface hepatitis. Immune activation in this context not only perpetuates hepatocyte injury but may also influence disease chronicity, especially when superimposed on metabolic or autoimmune susceptibilities.

5. Clinical Manifestations of Convergent Hepatic Complications

5.1 Steatohepatitis and Fibrosis

In patients with diabetes and metabolic syndrome, NAFLD is highly prevalent, and progression to NASH represents a critical turning point. When metabolic stress coexists with immune activation or hepatotoxic drug exposure, the transition from simple steatosis to steatohepatitis and fibrosis occurs more rapidly[37]. Hepatic stellate cells, the primary fibrogenic cells of the liver, are activated by pro-fibrotic cytokines such as transforming growth factor-β released from both damaged hepatocytes and infiltrating immune cells. Persistent inflammation and oxidative stress further drive extracellular matrix deposition, resulting in fibrosis and architectural remodeling of the liver.

5.2 Overlap Syndromes with Autoimmune Features

Overlap syndromes exemplify the convergence of metabolic, immune, and toxic pathways. Some patients present with clinical, serologic, and histologic features indicative of both NAFLD/NASH and autoimmune hepatitis[38]. Diagnosing these cases requires careful interpretation of autoantibody profiles, liver biopsy findings, and drug exposure history. Concomitant hepatotoxic medications or supplements may further complicate the clinical picture, necessitating a nuanced approach to management.

5.3 **Acute Liver Failure**

Although rare, the combination of metabolic stress, immune activation, and drug exposure can precipitate acute liver failure. In individuals with subclinical metabolic dysfunction, even therapeutic doses of hepatotoxic drugs such as acetaminophen may overwhelm antioxidant defenses like glutathione, lowering the threshold for hepatocellular necrosis[39]. The resulting rapid hepatocyte death, coupled with an amplified immune response, can culminate in fulminant hepatic failure, emphasizing the critical interplay of these convergent risk factors.

CONCLUSION

Hepatic complications arising from diabetes, autoantibodies, and drug toxicity do not occur in isolation. They converge through shared pathways of oxidative stress, immune activation, metabolic dysfunction, and cellular injury. Recognizing these interactions expands our understanding of liver disease beyond organ-specific models to integrated systems biology. Clinically, this perspective supports comprehensive diagnostic and therapeutic strategies that address metabolic, immune, and toxic contributors simultaneously. Ongoing research into convergent mechanisms will deepen insights and improve outcomes for patients with complex liver disease.

REFERENCES

1. Kalra A, Yetiskul E, Wehrle CJ, et al. Physiology, Liver. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535438/
2. Uroko, Robert I.., Adamude, Fatima A.., Egba, Simeon I., Ani, Chijioke C and 1 Ekpenyong, James E (2020) Hepatoprotective Effects of Methanol Extract of Acanthus montanus (acanthaceae) Leaves on Acetaminophen Induced Liver Injury in Rats. Pharmacologyonline, 1: 248-260
3. CI Ezekwe, CR Uzomba, OPC Ugwu. The effect of methanol extract of Talinumtriangulare (water leaf) on the hematology and some liver parameters of experimental rats*Global Journal of Biotechnology and Biochemistry 2013; 8(2) 51-60.*
4. Iovino P, Vellone E, Cedrone N, Riegel B. A Middle-Range Theory of Social Isolation in Chronic Illness. Int J Environ Res Public Health. 2023 Mar 10;20(6):4940. doi: 10.3390/ijerph20064940. PMID: 36981849; PMCID: PMC10049704.
5. Horgan S, Prorok J, Conn D, Checkland C, Saunders J, Watson-Borg B, Tinley L. Can 'What Is Known' about Social Isolation and Loneliness Interventions Sufficiently Inform the Clinical Practice of Health Care and Social Service Professionals Who Work with Older Adults? Exploring Knowledge-to-Practice Gaps. Healthcare. 2024; 12(11):1111. https://doi.org/10.3390/healthcare12111111
6. Ibiam, U. A., Alum, E. U., Orji, O. U., Aja, P. M., Ezeani, N. N., Ugwu, O. P. C. and Ekpono, E. U. Anti-Inflammatory Effects of *Buchholzia coriacea* Ethanol Leaf-Extract and Fractions in Freund's Adjuvant-Induced Rheumatoid Arthritic Albino Rats. *Indo American Journal of Pharmaceutical Sciences (IAJPS)*. 2018; **5** (7): 6341- 6357. https://doi.org/10.5281/zenodo.1311167.
7. Pervin M, de Haan JB. Dysregulated Redox Signaling and Its Impact on Inflammatory Pathways, Mitochondrial Dysfunction, Autophagy and Cardiovascular Diseases. Antioxidants (Basel). 2025 Oct 24;14(11):1278. doi: 10.3390/antiox14111278. PMID: 41300435; PMCID: PMC12649175.
8. GodfredYawson Scott and Felix Amekpor Emmanuel IfeanyiObeagu, P.C. UgwuOkechukwu , Esther U. Alum , GetrudeUzomaObeagu, Derrick Opoku (2023).
   Platelets as actors in inflammation and immunity: A fulcrum in immunity.*International Journal of Advanced Research in Biological Sciences, 10, (3), 81-89.*
9. Ogbodo John Onyebuchi, Chinazom Precious Agbo, Ugoci Olivia Njoku, Martins Obinna Ogugofor, Egba Simeon Ikechukwu, Stella Amarachi Ihim, Adaeze Chidiebere Echezona Kenneth Chibuike Brendan, Aman Babanrao Upaganlawar, and ChandrashekarDevidas Upasani. Alzheimer's Disease: Pathogenesis and Therapeutic Interventions, Current Aging Science, 2021; 21:1-25.
10. Chimaroke Onyeabo, Paul Anyiam Ndubuisi, Anthony Cemaluk Egbuonu, Prince Chimezie Odika, Simeon Ikechukwu Egba, Obedience Okon Nnana, Polycarp Nnacheta Okafor. Natural products-characterized Moringa oleifera leaves methanolic extractand anti-diabetic properties mechanisms of its fractions in streptozotocin-induced diabetic rats The Nigerian Journal of Pharmacy, 2022; 56(1):18-29

11. Godfrey Ogochukwu Ezema, Ndukaku Yusuf Omeh, Egba Simeon Ikechukwu, Ejiofor C Agbo, Adachukwu Ada Ikeyiand Emmanuel Ifeanyi Obeagu. Evaluation of Biochemical Parameters of Patients with Type 2 Diabetes Mellitus Based on Age and Gender in Umuahia (2023) Asian Journal of Dental and Health Sciences 2023; 3(2):32-36
12. Ugwu, O. P.C., Alum, E. U., Okon, M. B., Aja, P. M., Obeagu, E. I. and Onyeneke, E. C. Ethanol root extract and fractions of *Sphenocentrum jollyanum* abrogate hyperglycemia and low body weight in Streptozotocin-induced diabetic Wistar albino Rats, *RPS Pharmacy and Pharmacology Reports*. 2023; 2,1-6. https://doi.org/10.1093/rpsppr/rqad010.
13. Y Tanko, AI Salisu, KA Mohammed, SA Musa, A Jimoh, R Yusuf (2017). Anti-hyperglycaemic effects of rutin on blood glucose, oxidative stress biomarkers and lipid peroxidation in alloxan-induced hyperglycaemic wistar rats. *Nigerian Journal of Physiological Sciences, 32, (1), 91-96.*
14. Uti DE, Atangwho IJ, Alum EU, Egba SI, Ugwu OPC, Ikechukwu GC. Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Natural Product Communications. 2025;20(3). doi:10.1177/1934578x251323393
15. Lonardo A, Weiskirchen R. Insulin Resistance at the Crossroads of Metabolic Inflammation, Cardiovascular Disease, Organ Failure and Cancer. Biomolecules. 2025 Dec 17;15(12):1745. doi: 10.3390/biom15121745. PMID: 41463398; PMCID: PMC12730331.
16. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.A. (2025). Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obesity Medicine, 2025; 100622. https://doi.org/10.1016/j.obmed.2025.100622
17. Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. Compr Physiol. 2013 Apr;3(2):785-97. doi: 10.1002/cphy.c120026. PMID: 23720329; PMCID: PMC4748178.
18. Tsomidis I, Tsakou A, Voumvouraki A, Kouroumalis E. The Role of Kupffer Cells and Liver Macrophages in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease. Biomedicines. 2026; 14(1):151. https://doi.org/10.3390/biomedicines14010151
19. Fallatah HI, Akbar HO. Autoimmune hepatitis as a unique form of an autoimmune liver disease: immunological aspects and clinical overview. Autoimmune Dis. 2012;2012:312817. doi: 10.1155/2012/312817. Epub 2012 Dec 12. PMID: 23304455; PMCID: PMC3530748.
20. Mercado LA, Gil-Lopez F, Chirila RM, Harnois DM. Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview. Diagnostics. 2024; 14(4):382. https://doi.org/10.3390/diagnostics14040382
21. Gatselis NK, Zachou K, Koukoulis GK, Dalekos GN. Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. World J Gastroenterol. 2015 Jan 7;21(1):60-83. doi: 10.3748/wjg.v21.i1.60. PMID: 25574080; PMCID: PMC4284362.
22. Lung T, Sakem B, Risch L, Würzner R, Colucci G, Cerny A, Nydegger U. The complement system in liver diseases: Evidence-based approach and therapeutic options. J Transl Autoimmun. 2019 Sep 18;2:100017. doi: 10.1016/j.jtauto.2019.100017. PMID: 32743505; PMCID: PMC7388403.
23. Assis DN. Immunopathogenesis of Autoimmune Hepatitis. Clin Liver Dis (Hoboken). 2020 Apr 4;15(3):129-132. doi: 10.1002/cld.873. PMID: 32257125; PMCID: PMC7128031.
24. Vierling JM. Immunopathogenesis: Insights for current and future therapies. Clin Liver Dis (Hoboken). 2014 Mar 5;3(2):24-28. doi: 10.1002/cld.309. PMID: 31236265; PMCID: PMC6567855.
25. Khanam A, Chua JV, Kottilil S. Immunopathology of Chronic Hepatitis B Infection: Role of Innate and Adaptive Immune Response in Disease Progression. International Journal of Molecular Sciences. 2021; 22(11):5497. https://doi.org/10.3390/ijms22115497
26. Ikpozu EN, Offor CE, Igwenyi, I.O, Ibiam, U.A., Obaroh, I.O. et al. RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. Diabetes & Vascular Disease Research. 2025;22(2). doi:10.1177/14791641251334726
27. Alum, E.U. Optimizing patient education for sustainable self-management in type 2 diabetes. *Discov Public Health* **22**, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
28. Krishnamoorthy, R., Gatasheh, M. K., Subbarayan, S., Vijayalakshmi, P. Protective Role of Jimson Weed in Mitigating Dyslipidemia, Cardiovascular, and Renal Dysfunction in Diabetic Rat Models: In Vivo and in Silico Evidence. Natural Product Communications. 2024;19(12). doi:10.1177/1934578X241299279
29. David S, Hamilton JP. Drug-induced Liver Injury. US Gastroenterol Hepatol Rev. 2010 Jan 1;6:73-80. PMID: 21874146; PMCID: PMC3160634.

30. Marginean EC. Hepatotoxicity of Herbal and Dietary Supplements a Review of Diagnosis, Histologic Features, and Common Culprits: Bodybuilding and Weight Loss Supplements. Livers. 2025; 5(3):42. https://doi.org/10.3390/livers5030042
31. Francis P, Navarro VJ. Drug-Induced Hepatotoxicity. [Updated 2024 Sep 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557535/
32. Yuan L, Kaplowitz N. Mechanisms of drug-induced liver injury. Clin Liver Dis. 2013 Nov;17(4):507-18, vii. doi: 10.1016/j.cld.2013.07.002. Epub 2013 Aug 1. PMID: 24099014; PMCID: PMC3793205.
33. Villanueva-Paz M, Morán L, López-Alcántara N, Freixo C, Andrade RJ, Lucena MI, Cubero FJ. Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. Antioxidants. 2021; 10(3):390. https://doi.org/10.3390/antiox10030390
34. Ye H, Nelson LJ, Gómez Del Moral M, Martínez-Naves E, Cubero FJ. Dissecting the molecular pathophysiology of drug-induced liver injury. World J Gastroenterol. 2018 Apr 7;24(13):1373-1385. doi: 10.3748/wjg.v24.i13.1373. PMID: 29632419; PMCID: PMC5889818.
35. Jee A, Sernoskie SC, Uetrecht J. Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges. Int J Mol Sci. 2021 Mar 14;22(6):2954. doi: 10.3390/ijms22062954. PMID: 33799477; PMCID: PMC7998339.
36. Tiwari V, Shandily S, Albert J, Mishra V, Dikkatwar M, Singh R, Sah SK, Chand S. Insights into medication-induced liver injury: Understanding and management strategies. Toxicol Rep. 2025 Mar 1;14:101976. doi: 10.1016/j.toxrep.2025.101976. Erratum in: Toxicol Rep. 2025 Jun 16;14:102068. doi: 10.1016/j.toxrep.2025.102068. PMID: 40125297; PMCID: PMC11928981.
37. Miller DM, McCauley KF, Dunham-Snary KJ. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Clinical Implications and Therapeutic Advances. Endocrinol Diabetes Metab. 2025 Nov;8(6):e70132. doi: 10.1002/edm2.70132. PMID: 41255342; PMCID: PMC12627968.
38. Takahashi A, Arinaga-Hino T, Ohira H, Abe K, Torimura T, Zeniya M, Abe M, Yoshizawa K, Takaki A, Suzuki Y, Kang JH, Nakamoto N, Fujisawa T, Tanaka A, Takikawa H; Japan AIH Study Group (JAIHSG). Non-alcoholic fatty liver disease in patients with autoimmune hepatitis. JGH Open. 2018 Mar 30;2(2):54-58. doi: 10.1002/jgh3.12046. PMID: 30483564; PMCID: PMC6207019.
39. Ramachandran A, Jaeschke H. Mechanisms of acetaminophen hepatotoxicity and their translation to the human pathophysiology. J Clin Transl Res. 2017 Feb;3(Suppl 1):157-169. doi: 10.18053/jctres.03.2017S1.002. Epub 2017 Feb 12. PMID: 28670625; PMCID: PMC5489132.
40. Ugwu OPC, Offor CE, Ibiam UA, Ezugwu AL, Uraku AJ, Igwe CN. The effect of ethanol extract of Jatropha curcas on renal markers of chloroform intoxicated albino Wistar rats. Eur J Biol Sci. 2015;7(1):21–5.
41. Ugwu OPC, Nzubechukwu E. The effect of ethanol leaf extract of Jatropha curcas on chloroform-induced hepatotoxicity in albino rats. Glob J Biotechnol Biochem. 2015;10:11–5.
42. Ugwu OPC, Onwe SC, Okon MB. The effect of methanol extract of Rauwolfia vomitoria on lipid profile of chloroform-intoxicated Wistar albino rats. IAA J Sci Res. 2022;8(1):73–82.
43. Ugwu OPC. The effect of ethanol leaf extract of Rauwolfia vomitoria on hepatic markers of chloroform-intoxicated albino Wistar rats. IAA J Appl Sci. 2022;8(1):87–97.
44. Ugwu OPC. The effect of methanol leaf extract of Rauwolfia vomitoria on hepatic markers of chloroform-intoxicated albino Wistar rats. IAA J Appl Sci. 2022;8(1):76–86.
45. Aja PM, Ezeudeh NL, Umahi BG, Ugwu OPC, Enechi OC, Edwin N, et al. Hepato-protective effect of ethanol extract of Pterocarpus santalinoides leaf on carbon tetrachloride (CCl4)-induced albino rats. Caribb J Sci Technol. 2016;4(1):882–95.
46. Enechi OC, Okpe CC, Ibe GN, Omeje KO, Ugwu OPC. Effect of Buchholzia coriacea methanol extract on haematological indices and liver function parameters in Plasmodium berghei-infected mice. Global Vet. 2016;16(1):57–66.
47. Offor CE, Ibiam UA, Ugwu PC, Nwankwo H. The effect of ethanol leaf-extract of Gmelina arborea on liver enzymes. Eur J Biol Sci. 2015;7(1):38–40.
48. Offor CE, Nwankwegu NJ, Ugwu OPC, Aja PM. The effects of ethanol leaf-extract of Pterocarpus santalinoides on liver enzymes of albino rats. 2015.

49. Aja PM, Udeh SMC, Opajobi AO, Uzuegbu UE, Alum EU, Edwin N, et al. Hepato-protective effect of aqueous leaf-extract of Talinum triangulare in monosodium glutamate (MSG)-induced hepatic damage in albino rats. Indo Am J Pharm Sci. 2017;4(2):464–70.
50. Alum EU, Umoru GU, Uti DE, Aja PM, Ugwu OPC, Orji OU, et al. Hepato-protective effect of ethanol leaf extract of Datura stramonium in alloxan-induced diabetic albino rats. J Chem Soc Nigeria. 2022;47(5).
51. Orji OU, Ibiam UA, Aja PM, Uraku AJ, Inya-Agha OR, Ugwu OPC, et al. Hepatoprotective activity of ethanol extract of Vernonia ambigua against carbon tetrachloride-induced hepatotoxicity in albino rats. IOSR J Dent Med Sci. 2015;14:22–9.
52. Orji OU, Ibiam UA, Aloke C, Awoke J, Aja PM, Ugwu OPC, et al. Biochemical assessment of ethanol leaf extract of Cnidoscolus aconitifolius on liver integrity of albino rat treated with lead. Glob J Pharmacol. 2016;10(4):108–13.
53. Ezekwe CI, Ada AC, Ugwu OPC. Effects of methanol extract of Parkia biglobosa stem bark on the liver and kidney functions of albino rats. 2013.
54. Ezekwe CI, Uzomba CR, Ugwu OPC. The effect of methanol extract of Talinum triangulare (water leaf) on the hematology and some liver parameters of experimental rats. Glob J Biotechnol Biochem. 2013;8(2):51–60.
55. Ugwu OPC, Amasiorah VI. Review on health implications, benefits and biochemistry of alcohol intoxication. INOSR Exp Sci. 2020;6(1):62–74.
56. Ezeonwumelu JOC, Uhama KC, Ugwu OPC, Alum EU. Comprehensive overview of alcohol intoxication: mechanisms, effects, and interventions. Res Invent J Sci Exp Sci. 2024;3(1):12–20.
57. Nwaka AC, Ikechi-Agba MC, Ugwu OPC, Igwenyi IO, Agbafor KN, Ibiam UA, et al. The effects of ethanol extracts of Jatropha curcas on some hematological parameters of chloroform intoxicated rats. Am-Eur J Sci Res. 2015;10(1):45–9.
58. Ibiam UA, Ama-Udu, Egwu OA, Ugwu OPC. The protective effect of Gongronema latifolium leaf extract against hepatotoxicity of Rambo and Baygon mosquito coil smoke respectively in albino rats. World Appl Sci J. 2015;33(12):1915–22.
59. Odo CE, Nwodo OFC, Joshua PE, Ubani CS, Etim OE, Ugwu OPC. Effects of Bonny light crude oil on anti-oxidative enzymes and total proteins in Wistar rats. Afr J Biotechnol. 2012;11(98):16455–60.
60. Ozioko PC, Ugwu OPC, Chilaka FC, Ude S. Purification and characterization of beta-D-glucosidase from the digestive tracts of an African Giant Snail (Achatina achatina). 2013.
61. Ozioko PC, Ikeyi AP, Ugwu OPC. Review article: cellulases, their substrates, activity and assay methods. Exp. 2013;12(2):778–85.
62. Ezekwe CI, Okorie A, Ugwu OPC, Nwodo OFC, Egba SC. Blood pressure lowering effect of extract of Gongronema latifolium. Res J Pharm Biol Chem Sci. 2014;5(2):952.

CITE AS: Twesigye Davis (2026). Cross-Disease Hepatic Complications: How Diabetes, Autoantibodies, and Drug Toxicity Converge. IDOSR JOURNAL OF APPLIED SCIENCES 11(2):28-34. https://doi.org/10.59298/IDOSRJAS/2026/1122834